The Study of Cisplatin and Vinorelbine in Metastatic Uterine Cervical Cancer
Pimkhuan Kamnerdsupaphon MD*, Imjai Chitapanarux MD*, Ekkasit Tharavichitkul MD*, Vimol Sukthomya MD*, Vicharn Lorvidhaya MD*
Affiliation : * Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Objective : To determine the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment
of patients with metastatic cervical cancer.
Material and Method: a total of 17 patients were enrolled in the present study. The median age was 46 years
(38-65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment.
The patients were planned to receive cisplatin 80 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on day 1 and
8 every 3 weeks.
Results : Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%)
partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression
was the major toxicity. Grade 3-4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other
significant side effects were found.
Conclusion : Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma.
These results require confirmation.
Keywords : Uterine cervical neoplasms, Cisplatin, Vinblastine, Vinorelbine
